Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
YPrime's new glucometer/eCOA functionality offers a patient-centric, intuitive, and connected experience to clinical trial participants.
-
New York, July 13, 2023 (GLOBE NEWSWIRE) -- The global blood glucose monitoring system market size is expected to expand at ~10% CAGR from 2023 to 2033. The market is anticipated to garner a revenue...
-
New York, USA, April 10, 2023 (GLOBE NEWSWIRE) -- According to a report published by Research dive, the global tubeless insulin pump market is envisioned to generate a revenue of $2,837.6 million,...
-
Pune, India, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The global blood glucose monitoring system market size is anticipated to rise during the forecast period due to the increasing prevalence of diabetes...
-
New York, USA, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Blood Glucose Monitoring Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Blood Glucose...
-
New York, United States, June 29, 2022 (GLOBE NEWSWIRE) -- Diabetes is a life-threatening, chronic disorder for which there is no treatment. Diabetes is becoming a global pandemic affecting millions...
-
Pune, India, Aug. 16, 2021 (GLOBE NEWSWIRE) -- The global Blood Glucose Monitoring System Market is set to gain impetus from the emergence of innovative technologies, such as continuous BGM systems...
-
Pune, India, Nov. 12, 2020 (GLOBE NEWSWIRE) -- The global Blood Glucose Meter Market size is likely to expand considerably in the coming years due to advent of non-invasive devices. According to a...
-
T1D Exchange Teams with Tidepool to Leverage Device Data for Groundbreaking Study of Type 1 Diabetes
BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- T1D Exchange today announced a research partnership with Tidepool to better understand the link between patient reported experiences and the mild and...
-
Vigilant met or exceeded all human factors criteria for safety, comprehension and ease of useEarly evidence of clinical benefit was demonstrated by a 51 percent reduction in the proportion of blood...